Literature DB >> 32385143

Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.

A Finckh1, C Tellenbach2, L Herzog2,3, A Scherer2, B Moeller4, A Ciurea5, I von Muehlenen6, C Gabay1, D Kyburz7, L Brulhart8, R Müller9, P Hasler9, P Zufferey10.   

Abstract

BACKGROUND: Multiple biologic and targeted synthetic disease-modifying rheumatic drugs (b/tsDMARDs) are approved for the management of rheumatoid arthritis (RA), including TNF inhibitors (TNFi), bDMARDs with other modes of action (bDMARD-OMA) and Janus kinase inhibitors (JAKi). Combination of b/tsDMARDs with conventional synthetic DMARDs (csDMARDs) is recommended, yet monotherapy is common in practice.
OBJECTIVE: To compare drug maintenance and clinical effectiveness of three alternative treatment options for RA management.
METHODS: This observational cohort study was nested within the Swiss RA Registry. TNFi, bDMARD-OMA (abatacept or anti-IL6 agents) or the JAKi tofacitinib (Tofa) initiated in adult RA patients were included. The primary outcome was overall drug retention. We further analysed secondary effectiveness outcomes and whether concomitant csDMARDs modified effectiveness, adjusting for potential confounding factors.
RESULTS: 4023 treatment courses of 2600 patients were included, 1862 on TNFi, 1355 on bDMARD-OMA and 806 on Tofa. TNFi was more frequently used as a first b/tsDMARDs, at a younger age and with shorter disease duration. Overall drug maintenance was significantly lower with TNFi compared with Tofa [HR 1.29 (95% CI 1.14 to 1.47)], but similar between bDMARD-OMA and Tofa [HR 1.09 (95% CI 0.96 to 1.24)]. TNFi maintenance was decreased when prescribed without concomitant csDMARDs [HR: 1.27 (95% CI 1.08 to 1.49)], while no difference was observed for bDMARD-OMA or Tofa maintenance with respect to concomitant csDMARDs.
CONCLUSION: Tofa drug maintenance was comparable with bDMARDs-OMA and somewhat higher than TNFi. Concomitant csDMARDs appear to be required for optimal effectiveness of TNFi, but not for bDMARD-OMA or Tofa. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  abatacept; biological therapies; comparative effectiveness research; rheumatoid arthritis; tocilizumab; tumour necrosis alpha inhibitors

Mesh：

Substances：

Year:  2020        PMID： 32385143      PMCID： PMC7299517          DOI： 10.1136/rmdopen-2020-001174

Source DB:  PubMed          Journal:  RMD Open        ISSN： 2056-5933


  14 in total

1.  Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.

Authors:  Peter C Taylor; Edward C Keystone; Désirée van der Heijde; Michael E Weinblatt; Liliana Del Carmen Morales; Jaime Reyes Gonzaga; Sergey Yakushin; Taeko Ishii; Kahaku Emoto; Scott Beattie; Vipin Arora; Carol Gaich; Terence Rooney; Douglas Schlichting; William L Macias; Stephanie de Bono; Yoshiya Tanaka
Journal:  N Engl J Med       Date:  2017-02-16       Impact factor: 91.245

2.  Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.

Authors:  Roy Fleischmann; Eduardo Mysler; Stephen Hall; Alan J Kivitz; Robert J Moots; Zhen Luo; Ryan DeMasi; Koshika Soma; Richard Zhang; Liza Takiya; Svitlana Tatulych; Christopher Mojcik; Sriram Krishnaswami; Sujatha Menon; Josef S Smolen
Journal:  Lancet       Date:  2017-06-16       Impact factor: 79.321

3.  Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.

Authors:  Cem Gabay; Myriam Riek; Almut Scherer; Axel Finckh
Journal:  Rheumatology (Oxford)       Date:  2015-04-27       Impact factor: 7.580

4.  Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis.

Authors:  Felicity Buckley; Axel Finckh; Tom W J Huizinga; Fred Dejonckheere; Jeroen P Jansen
Journal:  J Manag Care Spec Pharm       Date:  2015-05

5.  Clinical quality management in rheumatoid arthritis: putting theory into practice. Swiss Clinical Quality Management in Rheumatoid Arthritis.

Authors:  E Uitz; J Fransen; T Langenegger; G Stucki
Journal:  Rheumatology (Oxford)       Date:  2000-05       Impact factor: 7.580

6.  The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden.

Authors:  Lars Erik Kristensen; Tore Saxne; Pierre Geborek
Journal:  Arthritis Rheum       Date:  2006-02

7.  Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.

Authors:  Michael E Weinblatt; Michael Schiff; Robert Valente; Désirée van der Heijde; Gustavo Citera; Cathy Zhao; Michael Maldonado; Roy Fleischmann
Journal:  Arthritis Rheum       Date:  2013-01

8.  Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study.

Authors:  Cem Gabay; Myriam Riek; Merete Lund Hetland; Ellen-Margrethe Hauge; Karel Pavelka; Matija Tomšič; Helena Canhao; Katerina Chatzidionysiou; Galina Lukina; Dan C Nordström; Elisabeth Lie; Ioan Ancuta; M Victoria Hernández; Piet L M C van Riel; Ronald van Vollenhoven; Tore K Kvien
Journal:  Ann Rheum Dis       Date:  2015-09-15       Impact factor: 19.103

9.  Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.

Authors:  Marina Amaral de Ávila Machado; Cristiano Soares de Moura; Steve Ferreira Guerra; Jeffrey R Curtis; Michal Abrahamowicz; Sasha Bernatsky
Journal:  Arthritis Res Ther       Date:  2018-03-23       Impact factor: 5.156

10.  Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.

Authors:  Cem Gabay; Paul Emery; Ronald van Vollenhoven; Ara Dikranian; Rieke Alten; Karel Pavelka; Micki Klearman; David Musselman; Sunil Agarwal; Jennifer Green; Arthur Kavanaugh
Journal:  Lancet       Date:  2013-03-18       Impact factor: 79.321
View more
  10 in total

1.  Tofacitinib for the treatment of rheumatoid arthritis: a real-world study in China.

Authors:  Yunzhen Shi; Yuesheng Xie; Guangfeng Zhang; Yuan Feng
Journal:  Intern Emerg Med       Date:  2021-09-24       Impact factor: 3.397

2.  Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis.

Authors:  Gerd R Burmester; Vivian P Bykerk; Maya H Buch; Yoshiya Tanaka; Hideto Kameda; Amy Praestgaard; Hubert van Hoogstraten; Antonio Fernandez-Nebro; Thomas Huizinga
Journal:  Rheumatology (Oxford)       Date:  2022-05-30       Impact factor: 7.046

Review 3.  JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future.

Authors:  Jacopo Angelini; Rossella Talotta; Rossana Roncato; Giulia Fornasier; Giorgia Barbiero; Lisa Dal Cin; Serena Brancati; Francesco Scaglione
Journal:  Biomolecules       Date:  2020-07-05

4.  Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010-2019 - a country with a national tender system for prescription of costly drugs.

Authors:  Alen Brkic; Andreas P Diamantopoulos; Espen Andre Haavardsholm; Bjørg Tilde Svanes Fevang; Lene Kristin Brekke; Liz Loli; Camilla Zettel; Erik Rødevand; Gunnstein Bakland; Pawel Mielnik; Glenn Haugeberg
Journal:  BMC Health Serv Res       Date:  2022-01-10       Impact factor: 2.655

5.  TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD.

Authors:  Anne Constanze Regierer; Rebecca Hasseli; Martin Schäfer; Bimba F Hoyer; Andreas Krause; Hanns-Martin Lorenz; Alexander Pfeil; Jutta Richter; Tim Schmeiser; Hendrik Schulze-Koops; Anja Strangfeld; Reinhard E Voll; Christof Specker; Ulf Mueller-Ladner
Journal:  RMD Open       Date:  2021-10

6.  Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland.

Authors:  Theresa Burkard; Enriqueta Vallejo-Yagüe; Thomas Hügle; Axel Finckh; Andrea Michelle Burden
Journal:  BMJ Open       Date:  2022-03-15       Impact factor: 2.692

7.  Unmet need for patient involvement in rheumatology registries and observational studies: a mixed methods study.

Authors:  Paul Studenic; Mandeep Sekhon; Loreto Carmona; Maarten de Wit; Elena Nikiphorou
Journal:  RMD Open       Date:  2022-08

8.  Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data.

Authors:  Andrei Barbulescu; Johan Askling; Katerina Chatzidionysiou; Helena Forsblad-d'Elia; Alf Kastbom; Ulf Lindström; Carl Turesson; Thomas Frisell
Journal:  Rheumatology (Oxford)       Date:  2022-10-06       Impact factor: 7.046

9.  Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.

Authors:  Kim Lauper; Michele Iudici; Denis Mongin; Sytske Anne Bergstra; Denis Choquette; Catalin Codreanu; René Cordtz; Diederik De Cock; Lene Dreyer; Ori Elkayam; Ellen-Margrethe Hauge; Doreen Huschek; Kimme L Hyrich; Florenzo Iannone; Nevsun Inanc; Lianne Kearsley-Fleet; Eirik Klami Kristianslund; Tore K Kvien; Burkhard F Leeb; Galina Lukina; Dan C Nordström; Karel Pavelka; Manuel Pombo-Suarez; Ziga Rotar; Maria Jose Santos; Anja Strangfeld; Patrick Verschueren; Delphine Sophie Courvoisier; Axel Finckh
Journal:  Ann Rheum Dis       Date:  2022-06-15       Impact factor: 27.973

Review 10.  Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis.

Authors:  Ilaria Bertoldi; Roberto Caporali
Journal:  Open Access Rheumatol       Date:  2021-07-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.